Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by a Randomized Phase-II Study of ICE Compared With Panobinostat Plus ICE for Patients With Relapsed and Refractory Classical Hodgkin Lymphoma.

Next Previous
Trial Profile

Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by a Randomized Phase-II Study of ICE Compared With Panobinostat Plus ICE for Patients With Relapsed and Refractory Classical Hodgkin Lymphoma.

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panobinostat (Primary) ; Carboplatin; Etoposide; Ifosfamide; Pegfilgrastim
  • Indications Hodgkin's disease
  • Focus Adverse reactions

Most Recent Events

  • 21 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
  • 06 Dec 2016 Status changed from active, no longer recruiting to discontinued due to high rates of grade 4 hematologic toxicities of Ifosfamide, Carboplatin and Etoposide + Panobinostat and limited additional benefit of Panobinostat in combination with ICE the investigation of Panbinostat in this study was terminated, according to the results published at 58th Annual Meeting and Exposition of the American Society of Hematology.
  • 06 Dec 2016 Final results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top